Table 3 Characteristics of cancers detected

From: Performance of transperineal template-guided mapping biopsy in detecting prostate cancer in the initial and repeat biopsy setting

Continuous variables

Number of biopsy sessions

 

1 (n=60)

2 (n=81)

3 (n=35)

4 (n=22)

P

Total (n=198)

 

Mean

Median

Mean

Median

Mean

Median

Mean

Median

 

Mean

Median

Number mapping cores

54.2

54.0

55.8

57.0

53.9

58.0

54.5

58.5

0.603

54.8

56.0

Mean % positive biopsies

22.4

13.4

15.9

10.9

15.5

12.5

17.7

6.4

0.256

18.0

12.1

Categorical variables

Number of patients with prostate cancer

 

Count (%)

Count (%)

Count (%)

Count (%)

P

Count (%)

Gleason score

      

 6

24 (40.0)

38 (46.9)

17 (48.6)

9 (40.9)

0.183

88 (44.4)

 7

26 (43.3)

37 (45.7)

10 (28.6)

8 (36.4)

 

81 (40.9)

 8–10

10 (16.7)

6 (7.4)

8 (22.9)

5 (22.7)

 

29 (14.6)

No. positive cores

      

 1–4

22 (36.7)

28 (34.6)

14 (40)

13 (59.1)

0.643

77 (38.9)

 5–12

21 (35.0)

34 (42)

13 (37.1)

3 (13.6)

 

71 (35.8)

 >12

17 (28.3)

19 (23.5)

8 (22.9)

6 (27.3)

 

50 (25.3)

Prebiopsy diagnosis

      

 PIN

0 (0)

3 (3.7)

1 (2.9)

0 (0)

0.002

4 (2.0)

 Elevated PSA

60 (100)

65 (80.2)

28 (80.0)

19 (86.4)

 

172 (86.9)

 ASAP

0 (0)

13 (16.0)

6 (17.1)

3 (13.6)

 

22 (11.1)

  1. Abbreviations: ASAP, atypical small acinar proliferation; PIN, prostatic intraepithelial neoplasia; PSA, prostate specific antigen.
  2. Italic indicates significance test.